PBNK-CARs against breast cancer (HER-2), NB (CD244), and CD19 + B-cell precursor cell ALL (CD19) (90) have demonstrated efficacy in preclinical studies, while two clinical trials are ongoing using modified haplo-identical PBNK cells with anti-CD19 CARs in B cell malignancies (NCT00995137 and NCT01974479) (89). This evidence concerns the gene CD19 and breast carcinoma.